Cerebrospinal Fluid Management - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cerebrospinal Fluid Management - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cerebrospinal Fluid Management Market by Product Type (CSF Shunts & Valves, External Drainage Systems [Drainage & Monitoring Systems, Drainage-Specific Systems, and CSF Drainage Catheters {Ventricular, Lumbar, and Others}], Anti-Siphon Devices, and Others), Age Group (Adult and Pediatric), End User (Hospitals and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of neurological conditions, increasing number of trauma & accidents, and increase in product development activities by key market players across the globe.

The global cerebrospinal fluid management market was valued at USD XX billion in 2023, growing at a CAGR of 4.78% during the forecast period from 2024 to 2030 to reach XX billion by 2030. The growing prevalence of neurological conditions like hydrocephalus, brain tumors, and intracranial hypertension is significantly boosting the demand for advanced cerebrospinal fluid (CSF) management systems. Additionally, the rise in trauma and accidents, which frequently result in traumatic brain injuries, is further driving the market, as these injuries require effective CSF management to ensure better patient outcomes. Furthermore, the ongoing product development activities by key market players are enhancing the capabilities and features of cerebrospinal fluid management, leading to innovations that improve patient safety further propelling the market growth during forecast period from 2024 to 2030.

Cerebrospinal Fluid Management Market Dynamics:

According to the recent data provided by the GLOBOCAN, in 2022, globally the estimated new cases of brain and central nervous system cancer was estimated to be 322,000 per 100,000 population and the projection were estimated to increase 474,000 per 100,000 population by 2045.

Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Nearly 80% of those affected reside in low- and middle-income countries.

Neurological disorders such as brain tumors significantly boost the market for cerebrospinal fluid management because they often lead to the disruption of normal cerebrospinal fluid flow or absorption, resulting in conditions like hydrocephalus or increased intracranial pressure. These disorders necessitate precise and effective management of cerebrospinal fluid to prevent severe complications and ensure optimal patient outcomes thereby escalating the overall market of cerebrospinal fluid management across the globe.

Additionally, as per the data provided by the World Health Organization (WHO) 2023, approximately 20 to 50 million people suffer from non-fatal road traffic accidents worldwide, every year. As road traffic accidents continue to be a leading cause of traumatic brain injuries worldwide, the demand for advanced cerebrospinal fluid management systems is expected to rise as when a severe head injury occurs, it can disrupt the normal flow and absorption of cerebrospinal fluid, leading to increased intracranial pressure and the risk of further complications hence, thereby escalating the overall market of cerebrospinal fluid management across the globe.

Along with the factors mentioned above, the increase in product development activities are also expected to aid in the growth of the cerebrospinal fluid management market. For instance, in March 2021, Anuncia Inc. received the """"Breakthrough Device Designation"""" for ReFlow™ System Mini by the US FDA. The device is to be used in the treatment of CSF disorders requiring shunting such as hydrocephalus.

However, the stringent regulatory product approval process, common risks associated with the devices such as infection, shunt malfunction, and improper drainage, among others may hinder the growth of cerebrospinal fluid management.

Cerebrospinal Fluid Management Market Segment Analysis:

Cerebrospinal Fluid Management Market by Product Type (CSF Shunts & Valves, External Drainage Systems [Drainage & Monitoring Systems, Drainage-Specific Systems, and CSF Drainage Catheters {Ventricular, Lumbar, and Others}], Anti-Siphon Devices, and Others), Age Group (Adult and Pediatric), End User (Hospitals and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the overall cerebrospinal fluid management market, the CSF shunts & valves are expected to hold the largest share in the year 2023. CSF shunts and valves play a crucial role in boosting the overall market for cerebrospinal fluid (CSF) management systems by addressing the essential need for effective regulation of CSF flow in patients with conditions like hydrocephalus and intracranial hypertension. These devices are designed to divert excess cerebrospinal fluid from the brain's ventricles to other parts of the body, such as the abdominal cavity, where it can be safely absorbed. Their ability to provide targeted, long-term solutions for managing abnormal CSF accumulation has made them indispensable in clinical practice. Innovations in shunt and valve technology, such as improvements in biocompatibility, miniaturization, and programmable features, have enhanced their effectiveness and patient outcomes. This has led to increased adoption and demand for advanced CSF management systems across hospitals and clinics. As a result, the market for CSF management systems has experienced significant growth, driven by the need for more precise, reliable, and minimally invasive solutions to manage complex neurological conditions.

Additionally, the ongoing strategic activities across the globe further spurs the market of CSF shunts & valves. For instance, in May 2024, CereVasc received the FDA IDE approval for the STRIDE Pivotal study of the eShunt System for treatment of normal pressure hydrocephalus.

Hence, all the above-mentioned factors are expected to generate considerable revenue of the segment pushing the overall growth of the global cerebrospinal fluid management market during the forecast period.

North America is expected to dominate the overall cerebrospinal fluid management market:

Among all the regions, North America is expected to hold the largest share in the global cerebrospinal fluid management market in 2023. The growing prevalence of traumatic brain injuries, neurological disorders such as epilepsy, Alzheimer’s, and Parkinson’s disease across the region is escalating the overall market of cerebrospinal fluid management across the region. Additionally, recent product developmental activities, and rising government initiatives are expected to aid in the growth of the North American cerebrospinal fluid management market during the forecast period from 2024 to 2030.

As per the recent data provided by Centre for Disease Control and Prevention (2024), in 2021, there were more than 586 traumatic brain injury-related hospitalizations per day in the United States. Additionally, as per the recent data provided by the Alzheimer’s Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Thus, these neurodegenerative conditions result in the progressive deterioration of brain cells, which can lead to disruptions in the normal production, circulation, or absorption of cerebrospinal fluid. Patients with advanced Parkinson’s and Alzheimer’s are more prone to develop hydrocephalus—a condition marked by the accumulation of cerebrospinal fluid in the brain's ventricles. This condition often requires the implantation of cerebrospinal fluid shunts or external drainage systems for management thereby escalating the overall market of cerebrospinal fluid management across the region.

Moreover, as per the recent data provided by the Centers for Disease Control and Prevention (2024) each year in United States, about 1,427 babies were born with spina bifida, or 1 in every 2,758 births in the country. Many babies born with spina bifida also develop hydrocephalus which may boost the demand for CSF management devices such as hydrocephalus shunts, eventually driving the CSF management market across the region growth during the forecast period.

Additionally, according to the recent data provided by the Brain Aneurysm Foundation (2024), an estimated 6.5 million people in the United States had an un-ruptured brain aneurysm. The annual rate of rupture in the country was approximately 8 – 10 per 100,000 people. About 30,000 people in the United States suffered a brain aneurysm rupture each year. A brain aneurysm ruptures every 18 minutes. It had been established that blood from a torn aneurysm can result in the blockage of CSF circulation leading to fluid buildup and increased pressure on the brain ultimately causing hydrocephalus. Therefore, the increase in number of patients suffering from brain aneurysms in the country is expected to drive the demand for CSF management devices, thereby contributing in the overall growth of the CSF management market in the North American region.

Furthermore, the increased emphasis on product development activities and high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for cerebrospinal fluid management. For instance, in July 2023, Anuncia Medical successfully launched second generation device, ReFlow™ Mini Flusher device, to treat hydrocephalus at several leading neurosurgical centers across the United States.

Therefore, the interplay of above mentioned various factors in the region are expected to boost the North America cerebrospinal fluid management market during the forecast period.

Cerebrospinal Fluid Management Market Key Players:

Some of the key market players operating in the cerebrospinal fluid management market include Medtronic PLC, B. Braun Melsungen AG, Neuromedex GmbH, Natus Medical Incorporated., Sophysa, Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, Desu Medical, Polyganics, CHRISTOPH MIETHKE GMBH & CO. KG, HpBio Proteses Inc., Wellong Instruments Co., Ltd., Möller Medical GmbH, CereVasc, Inc., Anuncia Inc., and others.

Recent Developmental Activities in the Cerebrospinal Fluid Management Market:

• In May 2024, FDA approved CereVasc’s eShunt system study for hydrocephalus.
• In November 2023, Pramand launched CraniSeal™ Dural Sealant, an absorbable polyethylene glycol (PEG) hydrogel that is applied with an applicator over sutures. This sealant prevents cerebrospinal fluid from leaking out of a cranial surgery incision site.
• In June 2023, Roche received FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making.

Key Takeaways From the Cerebrospinal Fluid Management Market Report Study:

• Market size analysis for current cerebrospinal fluid management size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the cerebrospinal fluid management market.
• Various opportunities available for the other competitors in the cerebrospinal fluid management market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current cerebrospinal fluid management market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for cerebrospinal fluid management market growth in the coming future?

Target Audience who can be Benefited From This Cerebrospinal Fluid Management Market Report Study:

• Cerebrospinal fluid management product providers
• Research organizations and consulting companies
• Cerebrospinal fluid management -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in cerebrospinal fluid management
• Various end-users who want to know more about the cerebrospinal fluid management market and the latest technological developments in the cerebrospinal fluid management market.

Frequently Asked Questions for the Cerebrospinal Fluid Management Market:

1. What are cerebrospinal fluid management?

Cerebrospinal fluid management devices are used in the treatment of CSF accumulation and leakage in events of hydrocephalus and injuries due to various reasons such as birth defects, trauma, and other causes. These include devices such as CSF shunts, dual sealants, and intracranial pressure monitoring devices among others.

2. What is the market for cerebrospinal fluid management?

The global cerebrospinal fluid management market was valued at USD XX billion in 2023, growing at a CAGR of 4.78% during the forecast period from 2024 to 2030 to reach XX billion by 2030.

3. What are the drivers for the cerebrospinal fluid management market?

The growing prevalence of neurological conditions like hydrocephalus, brain tumours, and intracranial hypertension is significantly boosting the demand for advanced cerebrospinal fluid (CSF) management systems. Additionally, the rise in trauma and accidents, which frequently result in traumatic brain injuries, is further driving the market, as these injuries require effective CSF management to ensure better patient outcomes. Furthermore, the ongoing product development activities by key market players are enhancing the capabilities and features of cerebrospinal fluid management, leading to innovations that improve patient safety further propelling the market growth during forecast period from 2024 to 2030.

4. Who are the key players operating in the cerebrospinal fluid management market?

Some of the key market players operating in the cerebrospinal fluid management market include Medtronic PLC, B. Braun Melsungen AG, Neuromedex GmbH, Natus Medical Incorporated., Sophysa, Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, Desu Medical, Polyganics, CHRISTOPH MIETHKE GMBH & CO. KG, HpBio Proteses Inc., Wellong Instruments Co., Ltd., Möller Medical GmbH, CereVasc, Inc., Anuncia Inc., and others.

5. Which region has the highest share in the cerebrospinal fluid management market?

Among all the regions, North America is expected to hold the largest share in the global cerebrospinal fluid management market in 2023. The growing prevalence of traumatic brain injuries, neurological disorders such as epilepsy, Alzheimer’s, and Parkinson’s disease across the region is escalating the overall market of cerebrospinal fluid management across the region. Additionally, recent product developmental activities, and rising government initiatives are expected to aid in the growth of the North American cerebrospinal fluid management market during the forecast period from 2024 to 2030.